Michael Bao

Industrial Execution Architect for FoodTech, Functional F&B & Nutrition Brands
Diagnostic Protocols Scale-up, thermodynamic stability, and industrial risk systems.

Strategy is the commercial intent. The supply chain is the grounded reality.

I architect Strategic Vendor Architectures (SVA) within the China-based manufacturing ecosystem to ensure boardroom ambitions survive the physical production reality. I translate manufacturing physics into diagnostic protocols that expose execution risk before commercial scale-up.

Work With Michael Read The SVA Blueprint

Field Experience

Since 2008

Core Methodology

SVA & TPI

Base

Global / China

Active Advisories // Archive
SVA-COM-21: Ingredient Transfer Control Window [UPDATED JUL. 29] An announced ingredient-business sale does not prove a material has changed. It does create a control window: confirm the approved specification, manufacturing site, quality ownership, and change-notification path before close. Open Advisory → SVA-REG-19: Product-Identity Release Failure [UPDATED JUL. 29] A sausage inclusion in a product labelled vegetarian created an undeclared-soy recall. Product identity, formula status, and allergen disclosure must close together at release. Open Advisory → SVA-REG-20: Source-Lot Traceability Anchor [UPDATED JUL. 29] A multi-brand egg recall shows why traceability must resolve to the physical source and lot, not only the brand on the front of the carton. Plant and date codes are the containment boundary. Open Advisory →

Intelligence Matrix

Intelligence Layers
01Execution Gap 02SVA Architecture 03TPI & Scale-Up Physics 04Sub-Tier Risk 05Capital vs. Physics
SVA Blueprint — Strategic Vendor Architecture integration matrix for decoupling commercial valuation from manufacturing volatility
Core Methodology (Public)

The SVA Blueprint:
Architecting Resilience

The structural fragility of the transactional vendor-selection model, and the exact physical protocols required to decouple your commercial valuation from manufacturing volatility.

Access The Manual
Alternative Protein Has Entered the Integration Phase — The Execution Gap Issue 004
Latest Insight // Issue #004 // Jul. 24

Alternative Protein Has Entered the Integration Phase

The next advantage is ownership of the system that makes a protein commercially repeatable.

 Global Choke Points — Hormuz disruption analysis for CPG supply chain adaptation
Featured Case // Public // Apr. 2026

Global Choke Points: The Hormuz Disruption

How a 95% drop in strait traffic becomes a packaging, temperature, and replenishment stress test for CPG supply chains.
View All Insights
Engagement Intake

Work With Michael

Independent, brand-side eyes on your China manufacturing reality. Based in Beijing. Inside the ecosystem since 2008.

Fixed-Scope Diagnostic

China Supplier Second Opinion

An independent review of one China supplier before your next PO: verified capability vs. claimed capability, sub-tier and subcontracting exposure, and the specific failure points for your product category. 8–12 page report plus a 60-minute walkthrough call, delivered in 5–7 working days.

Fixed fee — from USD 1,500, quoted upfront.

Engagement capacity: two diagnostic slots per month

Monthly Retainer

On-the-Ground Representation

Your brand's own presence inside your China supply chain: scheduled factory oversight visits, pre-shipment independent verification before release, immediate escalation of deviations, and your seat in supplier meetings — attended on your behalf, in Mandarin.

Retainer — from USD 3,000 / month.

Engagement capacity: limited concurrent retainers

Independent and vendor-agnostic. Zero commissions from factories, suppliers, or transactions — ever. Larger architecture engagements are scoped individually. Corporate domains strictly required.

We use the details you submit to review and respond to this request. See the Privacy Policy for processing, service-provider, retention, and rights information.